Further, by assessing changes in histone modifications in the CDKN1A promoter region, which regulates the E2F1 transcription factor, we determined that ARID1A deletion downregulates CDKN1A acetylation, diminishes P21 protein transcription, and initiates a cascade of tumor drug resistance responses. This evidence concerns the gene ARID1A and neoplasm.